RxDoctor Payments Data

Sachin Patel, MD

Cardiovascular Disease · Mishawaka, INNPI 1770587321

Payments from drug & device makers

$13,830in general payments, 2019–2025

Across 779 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Novartis$1K
  • Esperion Therapeutics, Inc.$1K
  • AstraZeneca$895
  • Pfizer$880
  • Amgen$779
  • plus $7K from 40 others

What the payments were for

  • Food & beverage$13,830100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,830 in reported general payments places this provider in the 75th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$215,669
Medicare patients
1,260
Services billed
2,970

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban681$831,129
XareltoRivaroxaban304$381,873
EntrestoSacubitril/Valsartan174$209,921
NexlizetBempedoic Acid/Ezetimibe125$85,378
MultaqDronedarone Hcl49$79,378
JardianceEmpagliflozin24$30,705
Repatha SureclickEvolocumab16$20,872
Flecainide Acetate225$10,094
VascepaIcosapent Ethyl19$9,428
NexletolBempedoic Acid11$7,359
Dabigatran EtexilateDabigatran Etexilate Mesylate15$6,718
CorlanorIvabradine Hcl11$6,650
Ranolazine ErRanolazine67$4,783
Propafenone Hcl45$4,333
Atorvastatin Calcium612$4,206

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$880$831,129681 claims
Johnson & JohnsonXarelto$1,510$381,873304 claims
NovartisEntresto$1,426$209,921174 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$1,031$92,736136 claims
Sanofi-aventis U.S. LLCMultaq$574$79,37849 claims
Boehringer IngelheimJardiance$455$30,70524 claims
AmgenCorlanor$779$6,65011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Mishawaka

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →